MA53124B1 - Agents de dégradation sélectifs des récepteurs des oestrogènes - Google Patents
Agents de dégradation sélectifs des récepteurs des oestrogènesInfo
- Publication number
- MA53124B1 MA53124B1 MA53124A MA53124A MA53124B1 MA 53124 B1 MA53124 B1 MA 53124B1 MA 53124 A MA53124 A MA 53124A MA 53124 A MA53124 A MA 53124A MA 53124 B1 MA53124 B1 MA 53124B1
- Authority
- MA
- Morocco
- Prior art keywords
- estrogen receptor
- selective estrogen
- receptor degraders
- degraders
- serd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Finger-Pressure Massage (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
L'invention concerne de nouveaux agents de dégradation sélectifs des récepteurs des oestrogènes (serd) selon la formule :, des sels pharmaceutiquement acceptables de ceux-ci, et des compositions pharmaceutiques de ceux-ci, formule dans laquelle l'un parmi r1 et r2 est indépendamment choisi parmi cl, f, -cf3 ou -ch3, et l'autre est l'hydrogène, et des procédés pour leur utilisation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697100P | 2018-07-12 | 2018-07-12 | |
| PCT/US2019/041334 WO2020014435A1 (fr) | 2018-07-12 | 2019-07-11 | Agents de dégradation sélectifs des récepteurs des oestrogènes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53124A MA53124A (fr) | 2021-05-19 |
| MA53124B1 true MA53124B1 (fr) | 2023-02-28 |
Family
ID=67470734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53124A MA53124B1 (fr) | 2018-07-12 | 2019-07-11 | Agents de dégradation sélectifs des récepteurs des oestrogènes |
| MA53126A MA53126B1 (fr) | 2018-07-12 | 2019-07-11 | Agents de dégradation sélectifs du récepteur des oestrogènes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53126A MA53126B1 (fr) | 2018-07-12 | 2019-07-11 | Agents de dégradation sélectifs du récepteur des oestrogènes |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US10654866B2 (fr) |
| EP (2) | EP3820873B1 (fr) |
| JP (6) | JP6995241B2 (fr) |
| KR (3) | KR102783756B1 (fr) |
| CN (2) | CN117379428A (fr) |
| AR (1) | AR115694A1 (fr) |
| AU (2) | AU2019299947B2 (fr) |
| BR (1) | BR122023025061A2 (fr) |
| CA (1) | CA3105501C (fr) |
| CL (1) | CL2021000045A1 (fr) |
| CO (1) | CO2021000043A2 (fr) |
| CR (1) | CR20210007A (fr) |
| DK (1) | DK3820873T3 (fr) |
| EA (1) | EA202092975A1 (fr) |
| EC (1) | ECSP21001770A (fr) |
| ES (1) | ES2933980T3 (fr) |
| FI (1) | FI3820873T3 (fr) |
| HR (1) | HRP20230009T1 (fr) |
| HU (1) | HUE060963T2 (fr) |
| IL (3) | IL289871B2 (fr) |
| JO (1) | JOP20210005A1 (fr) |
| LT (1) | LT3820873T (fr) |
| MA (2) | MA53124B1 (fr) |
| MD (1) | MD3820873T2 (fr) |
| MX (2) | MX2021000375A (fr) |
| MY (1) | MY198962A (fr) |
| PE (1) | PE20210400A1 (fr) |
| PH (1) | PH12021550049A1 (fr) |
| PL (1) | PL3820873T3 (fr) |
| PT (1) | PT3820873T (fr) |
| RS (1) | RS63809B1 (fr) |
| SA (1) | SA521421008B1 (fr) |
| SG (1) | SG11202100148TA (fr) |
| SI (1) | SI3820873T1 (fr) |
| TW (1) | TWI702219B (fr) |
| UA (1) | UA127507C2 (fr) |
| WO (1) | WO2020014435A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113248494A (zh) | 2015-10-01 | 2021-08-13 | 奥列马制药公司 | 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物 |
| TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| SG11202100145YA (en) * | 2018-07-12 | 2021-02-25 | Lilly Co Eli | Selective estrogen receptor degraders |
| AU2020311337A1 (en) | 2019-07-07 | 2022-01-20 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| US12528768B2 (en) | 2019-12-09 | 2026-01-20 | Sanofi | Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) * | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| CN116782895A (zh) * | 2020-11-23 | 2023-09-19 | 赛诺菲 | 包含阿贝西利和6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸的组合 |
| EP4294394A1 (fr) * | 2021-02-16 | 2023-12-27 | Genentech, Inc. | Traitement du cancer du sein à l'aide de polythérapies comprenant du gdc-9545 et de l'abémaciclib ou du ribociclib |
| CN114957114A (zh) * | 2021-02-26 | 2022-08-30 | 冷志 | 一种4-溴-3-氯-7-甲氧基喹啉的合成方法 |
| CN117042771A (zh) * | 2021-03-09 | 2023-11-10 | 伊莱利利公司 | 使用serd给药方案的组合治疗癌症的方法 |
| TWI837605B (zh) * | 2021-03-09 | 2024-04-01 | 美商美國禮來大藥廠 | 使用serd組合給藥方案治療癌症之方法 |
| TWI894443B (zh) * | 2021-03-16 | 2025-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| KR102743629B1 (ko) * | 2022-02-01 | 2024-12-17 | 일라이 릴리 앤드 캄파니 | 선택적 에스트로겐 수용체 분해제의 제조 방법 |
| TW202430176A (zh) | 2022-10-17 | 2024-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| WO2024097206A1 (fr) | 2022-11-02 | 2024-05-10 | Petra Pharma Corporation | Inhibiteurs chroménones allostériques de la phosphoinositide 3-kinase (pi3k) pour le traitement d'une maladie |
| CN120187416A (zh) | 2022-11-11 | 2025-06-20 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| US20240180893A1 (en) | 2022-11-17 | 2024-06-06 | Astrazeneca Ab | Methods of treatment of breast cancer |
| AU2024268541A1 (en) | 2023-05-05 | 2025-11-20 | Eli Lilly And Company | Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer |
| CN121079090A (zh) | 2023-05-11 | 2025-12-05 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的parp1抑制剂和选择性雌激素降解剂的组合 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1395563B1 (fr) * | 2001-05-22 | 2006-03-29 | Eli Lilly And Company | 1,2,3,4-tetrahydroquinoline 2-substituees et leurs derives, ainsi que leurs composition et leurs procedes |
| US7329654B2 (en) * | 2001-12-19 | 2008-02-12 | Janssen Pharmaceutica N.V. | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
| MXPA04010433A (es) * | 2002-04-19 | 2005-08-19 | Signal Pharm Inc | Compuestos benzopiranona, composiciones de estos y los metodos para el tratamiento con estos. |
| WO2005073204A1 (fr) | 2004-01-22 | 2005-08-11 | Eli Lilly And Company | Modulateurs selectifs du recepteur des oestrogenes pour le traitement de symptomes vasomoteurs |
| US20080221163A1 (en) * | 2005-01-18 | 2008-09-11 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
| JP6389517B2 (ja) | 2013-06-19 | 2018-09-12 | セラゴン ファーマシューティカルズ， インク． | アゼチジンエストロゲン受容体調節因子及びその使用 |
| CN112375077A (zh) * | 2014-12-18 | 2021-02-19 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| US9845291B2 (en) * | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| WO2018108954A1 (fr) | 2016-12-12 | 2018-06-21 | F. Hoffmann-La Roche Ag | Procédé de préparation de 2-(3-(fluorométhyl)azétidin-1-yl)éthan-1-ol |
| SG11202100145YA (en) * | 2018-07-12 | 2021-02-25 | Lilly Co Eli | Selective estrogen receptor degraders |
| TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
-
2019
- 2019-07-02 TW TW108123257A patent/TWI702219B/zh active
- 2019-07-03 AR ARP190101886A patent/AR115694A1/es active IP Right Grant
- 2019-07-11 PT PT197459258T patent/PT3820873T/pt unknown
- 2019-07-11 CN CN202311312431.7A patent/CN117379428A/zh active Pending
- 2019-07-11 BR BR122023025061-3A patent/BR122023025061A2/pt not_active Application Discontinuation
- 2019-07-11 KR KR1020237034781A patent/KR102783756B1/ko active Active
- 2019-07-11 UA UAA202100102A patent/UA127507C2/uk unknown
- 2019-07-11 WO PCT/US2019/041334 patent/WO2020014435A1/fr not_active Ceased
- 2019-07-11 MY MYPI2021000056A patent/MY198962A/en unknown
- 2019-07-11 JP JP2021500536A patent/JP6995241B2/ja active Active
- 2019-07-11 MA MA53124A patent/MA53124B1/fr unknown
- 2019-07-11 PE PE2020002017A patent/PE20210400A1/es unknown
- 2019-07-11 KR KR1020217000466A patent/KR102550538B1/ko active Active
- 2019-07-11 DK DK19745925.8T patent/DK3820873T3/da active
- 2019-07-11 CR CR20210007A patent/CR20210007A/es unknown
- 2019-07-11 AU AU2019299947A patent/AU2019299947B2/en active Active
- 2019-07-11 SG SG11202100148TA patent/SG11202100148TA/en unknown
- 2019-07-11 LT LTEPPCT/US2019/041334T patent/LT3820873T/lt unknown
- 2019-07-11 US US16/508,745 patent/US10654866B2/en active Active
- 2019-07-11 KR KR1020227044200A patent/KR102589886B1/ko active Active
- 2019-07-11 MA MA53126A patent/MA53126B1/fr unknown
- 2019-07-11 EA EA202092975A patent/EA202092975A1/ru unknown
- 2019-07-11 HR HRP20230009TT patent/HRP20230009T1/hr unknown
- 2019-07-11 EP EP19745925.8A patent/EP3820873B1/fr active Active
- 2019-07-11 CN CN201980046849.3A patent/CN112638916B/zh active Active
- 2019-07-11 PL PL19745925.8T patent/PL3820873T3/pl unknown
- 2019-07-11 RS RS20221142A patent/RS63809B1/sr unknown
- 2019-07-11 MX MX2021000375A patent/MX2021000375A/es unknown
- 2019-07-11 MD MDE20210462T patent/MD3820873T2/ro unknown
- 2019-07-11 CA CA3105501A patent/CA3105501C/fr active Active
- 2019-07-11 SI SI201930406T patent/SI3820873T1/sl unknown
- 2019-07-11 EP EP22201995.2A patent/EP4155310A1/fr active Pending
- 2019-07-11 FI FIEP19745925.8T patent/FI3820873T3/fi active
- 2019-07-11 JO JOP/2021/0005A patent/JOP20210005A1/ar unknown
- 2019-07-11 IL IL289871A patent/IL289871B2/en unknown
- 2019-07-11 HU HUE19745925A patent/HUE060963T2/hu unknown
- 2019-07-11 ES ES19745925T patent/ES2933980T3/es active Active
-
2020
- 2020-05-18 US US16/876,819 patent/US11117902B2/en active Active
-
2021
- 2021-01-06 CO CONC2021/0000043A patent/CO2021000043A2/es unknown
- 2021-01-07 CL CL2021000045A patent/CL2021000045A1/es unknown
- 2021-01-08 PH PH12021550049A patent/PH12021550049A1/en unknown
- 2021-01-10 IL IL280065A patent/IL280065B/en unknown
- 2021-01-11 MX MX2023006047A patent/MX2023006047A/es unknown
- 2021-01-12 EC ECSENADI20211770A patent/ECSP21001770A/es unknown
- 2021-01-12 SA SA521421008A patent/SA521421008B1/ar unknown
- 2021-09-02 US US17/465,066 patent/US11634426B2/en active Active
- 2021-12-14 JP JP2021202668A patent/JP7009672B1/ja active Active
-
2022
- 2022-01-12 JP JP2022003022A patent/JP7241211B2/ja active Active
- 2022-06-08 AU AU2022203969A patent/AU2022203969B2/en active Active
- 2022-08-14 IL IL295598A patent/IL295598B2/en unknown
-
2023
- 2023-03-06 JP JP2023033486A patent/JP7557564B2/ja active Active
- 2023-03-15 US US18/121,667 patent/US11993608B2/en active Active
-
2024
- 2024-09-13 JP JP2024159222A patent/JP7746496B2/ja active Active
-
2025
- 2025-09-17 JP JP2025154293A patent/JP2025186400A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53124B1 (fr) | Agents de dégradation sélectifs des récepteurs des oestrogènes | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| MA31419B1 (fr) | Derives de pyridine | |
| MA29791B1 (fr) | Composes therapeutiques. | |
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| BR112020001825A2 (pt) | compostos e métodos para a degradação direcionada de receptor de androgênio | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| MA31766B1 (fr) | Composés organiques | |
| MA39043A1 (fr) | Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs | |
| TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
| EA200700099A1 (ru) | Производные пиридина | |
| SE0300119D0 (sv) | Novel compounds | |
| MA30999B1 (fr) | Composés. | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| MA33836B1 (fr) | Compositions pharmaceutiques contenant des ligands des récepteurs sigma | |
| MA56883B1 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| MA33132B1 (fr) | Derives pyrazole utilises comme antagonistes du recepteur ccr4 | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| TNSN08137A1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques | |
| MA31761B1 (fr) | Nouveaux inhibiteurs de seh et leur utilisation | |
| MA34760B1 (fr) | Composés et leurs utilisation | |
| MA34553B1 (fr) | Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué | |
| MA41494B1 (fr) | Composés benzoxaborole substitués en position 4 et utilisations associées | |
| UA84896C2 (ru) | Производные гидронопола как агонисты человеческих рецепторов orl1 | |
| MA70477B1 (fr) | Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques |